Comments
Dr. Reddy’s Laboratories Ltd has launched Fulvestrant Injection per single-dose syringe, a therapeutic equivalent generic version of Faslodex (fulvestrant) Injection approved by the U.S. Food and Drug Administration (USFDA).
The Faslodex brand and generic market had U.S. sales of approximately $407 million for the most recent twelve months ending in June 2020 according to IQVIA Health
Dr. Reddy’s Fulvestrant Injection per Single-dose Syringe is available in a carton containing two 5 mL single-dose prefilled syringes. Faslodex is a trademark of the AstraZeneca group of companies.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.